Price History
Supriya Lifescience reports a significant 24% EPS growth over the past three years, boosting revenue to ₹7.4 billion last year. Impressively, company insiders hold a substantial 68% stake worth approximately ₹43 billion. Notably, the CEO's modest remuneration of ₹2.5 million reflects an alignment with shareholder interests.
Supriya Lifescience is set to announce its financial results for the fiscal year 2026 on May 27, 2026. The board might also suggest a dividend distribution. Note that the trading window remains closed until 48 hours post-results.
Supriya Lifesciences has successfully passed the US Food and Drug Administration (FDA) inspection, indicating their manufacturing unit now complies with U.S. safety and quality standards for pharmaceuticals. This achievement marks a significant milestone in expanding their global market reach.
Supriya Lifescience's Maharashtra facility has received Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA), following a recent inspection (Feb 2-6, 2026). This VAI status indicates one minor observation was noted during the inspection, but it has since been resolved.
Supriya Lifescience's recent US FDA inspection concluded with a single minor issue, earning them a VAI (Voluntary Action Indicated) rating. This indicates the company is taking corrective actions to address the identified issue.
In the final quarter of this year, Madhu Kela increased his ownership in Supriya Lifesciences by a modest 0.4%. This move indicates potential confidence or interest in the company's future performance.